173 related articles for article (PubMed ID: 38341600)
21. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
[TBL] [Abstract][Full Text] [Related]
22. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
[TBL] [Abstract][Full Text] [Related]
23. Inhibitor of growth 2 regulates the high glucose-induced cell cycle arrest and epithelial-to-mesenchymal transition in renal proximal tubular cells.
Ma Y; Yan R; Wan Q; Lv B; Yang Y; Lv T; Xin W
J Physiol Biochem; 2020 Aug; 76(3):373-382. PubMed ID: 32424454
[TBL] [Abstract][Full Text] [Related]
24. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
[TBL] [Abstract][Full Text] [Related]
25. Aberrant expression of NEDD4L disrupts mitochondrial homeostasis by downregulating CaMKKβ in diabetic kidney disease.
Han F; Wu S; Dong Y; Liu Y; Sun B; Chen L
J Transl Med; 2024 May; 22(1):465. PubMed ID: 38755664
[TBL] [Abstract][Full Text] [Related]
26. Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-β1/Smads Pathway.
Wu M; Guo Y; Wu Y; Xu K; Lin L
Front Pharmacol; 2021; 12():696472. PubMed ID: 34135764
[No Abstract] [Full Text] [Related]
27. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Burke RM; Lighthouse JK; Mickelsen DM; Small EM
Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
[TBL] [Abstract][Full Text] [Related]
28. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
[TBL] [Abstract][Full Text] [Related]
29. Sitagliptin ameliorates renal tubular injury in diabetic kidney disease via STAT3-dependent mitochondrial homeostasis through SDF-1α/CXCR4 pathway.
Zhang Q; He L; Dong Y; Fei Y; Wen J; Li X; Guan J; Liu F; Zhou T; Li Z; Fan Y; Wang N
FASEB J; 2020 Jun; 34(6):7500-7519. PubMed ID: 32281218
[TBL] [Abstract][Full Text] [Related]
30. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
[TBL] [Abstract][Full Text] [Related]
31. USP22 aggravated diabetic renal tubulointerstitial fibrosis progression through deubiquitinating and stabilizing Snail1.
Zhao X; He X; Wei W; Huang K
Eur J Pharmacol; 2023 May; 947():175671. PubMed ID: 37001578
[TBL] [Abstract][Full Text] [Related]
32. Acetyl-CoA synthetase 2 promotes diabetic renal tubular injury in mice by rewiring fatty acid metabolism through SIRT1/ChREBP pathway.
Lu J; Li XQ; Chen PP; Zhang JX; Li L; Wang GH; Liu XQ; Jiang CM; Ma KL
Acta Pharmacol Sin; 2024 Feb; 45(2):366-377. PubMed ID: 37770579
[TBL] [Abstract][Full Text] [Related]
33. YME1L-mediated mitophagy protects renal tubular cells against cellular senescence under diabetic conditions.
Luo Y; Zhang L; Su N; Liu L; Zhao T
Biol Res; 2024 Mar; 57(1):10. PubMed ID: 38494498
[TBL] [Abstract][Full Text] [Related]
34. CD36 deletion ameliorates diabetic kidney disease by restoring fatty acid oxidation and improving mitochondrial function.
Niu H; Ren X; Tan E; Wan X; Wang Y; Shi H; Hou Y; Wang L
Ren Fail; 2023; 45(2):2292753. PubMed ID: 38097943
[TBL] [Abstract][Full Text] [Related]
35. Modified Hu-lu-ba-wan protects diabetic glomerular podocytes via promoting PKM2-mediated mitochondrial dynamic homeostasis.
Gong M; Guo Y; Dong H; Wu F; He Q; Gong J; Lu F
Phytomedicine; 2024 Jan; 123():155247. PubMed ID: 38128393
[TBL] [Abstract][Full Text] [Related]
36. Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP/TAZ activation.
Feng L; Chen Y; Li N; Yang X; Zhou L; Li H; Wang T; Xie M; Liu H
Life Sci; 2023 Jun; 322():121671. PubMed ID: 37023953
[TBL] [Abstract][Full Text] [Related]
37. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
[TBL] [Abstract][Full Text] [Related]
38. Glis2 inhibits the epithelial-mesenchymal transition and apoptosis of renal tubule cells by regulating the β-catenin signalling pathway in diabetic kidney disease.
He L; Li Q; Du C; Xue Y; Yu P
Biochem Biophys Res Commun; 2022 Jun; 607():73-80. PubMed ID: 35367831
[TBL] [Abstract][Full Text] [Related]
39. Irisin Ameliorates Renal Tubulointerstitial Fibrosis by Regulating the Smad4/β-Catenin Pathway in Diabetic Mice.
Yang Z; Wei J; Wang Y; Du Y; Song S; Li J; Su Z; Shi Y; Wu H
Diabetes Metab Syndr Obes; 2023; 16():1577-1593. PubMed ID: 37292142
[TBL] [Abstract][Full Text] [Related]
40. Sirt1 inhibits renal tubular cell epithelial-mesenchymal transition through YY1 deacetylation in diabetic nephropathy.
Du L; Qian X; Li Y; Li XZ; He LL; Xu L; Liu YQ; Li CC; Ma P; Shu FL; Lu Q; Yin XX
Acta Pharmacol Sin; 2021 Feb; 42(2):242-251. PubMed ID: 32555442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
